A DNA Vaccine for Crimean Congo Hemorrhagic Fever Protects Against Disease and Death in Two Lethal Mouse Models
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus capable of causing a severe hemorrhagic fever disease in humans. There are currently no licensed vaccines to prevent CCHFV infection. We developed a DNA vaccine expressing the M-segment glycoprotein genes of CCHFV and assessed its immunogenicity and protective efficacy in two lethal mouse models of disease: type I interferon receptor knockout (IFNAR-/-) mice; and a novel transiently immune suppressed (IS) mouse model. Vaccination of mice by muscle electroporation of the M-segment DNA vaccine elicited strong antigen-specific humoral immune responses with neutralizing titers after three vaccinations in both IFNAR-/- and IS mouse models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 18, 2017
- Accession Number
- AD1035792
Entities
People
- Aura R. Garrison
- Carolyn M. Six
- Catherine V. Badger
- Charles J. Shoemaker
- Collin J. Fitzpatrick
- Connie S Schmaljohn
- Drew Hannaman
- Eric Bergeron
- Jacqueline D. Martin
- Jeffrey W. Koehler
- John J Suschak
- Joseph W. Golden
- Marko Zivcec
- Michelle J. Richards
Organizations
- United States Army Medical Research Institute of Infectious Diseases